Table 4

Change in NFS after HCT stratified by patient characteristics

FactorNo. at HCTNo. (%) evaluable for most recent NFSTime to most recent NFS, y, median (range)Change in NFS, IQR, median (range)P
Overall 60     
Loes score at HCT     < .01 
    < 10 30 26 (87) 2.9 (0.2-8.3) 0 (−1 to 20), (0-1)  
    ≥ 10 30 18 (60) 2.1 (0.8-6.6) 7.5 (0-23), (4-19)  
NFS at HCT     < .01 
    0 23 20 (87) 2.2 (0.2-8.3) 0 (0-8), (0-0)  
    ≥ 1 37 24 (65) 2.3 (0.8-7.2) 7 (−1 to 23), (1-17.5)  
Performance IQ at HCT     < .01 
    ≥ 80 29 23 (79) 3.1 (0.5-8.5) 0 (−1 to 22), (0-1)  
    < 80 22 16 (73) 1 (0.2-5.2) 8 (0-23), (3-17.5)  
Full Scale IQ at HCT     < .01 
    ≥ 80 26 20 (77) 3.5 (0.5-8.5) 0 (−1 to 12), (0-1)  
    < 80 20 14 (70) 1 (0.2-5.2) 11 (0-23), (2-20)  
Donor chimerism at day 60     < .01 
    > 80% 30 29 (97) 3.1 (0.2-8.5) 0 (−1 to 20), (0-7)  
    ≤ 80% 19 16 (84) 0.5 (0.2-2) 8 (0-23), (6-20.5)  
FactorNo. at HCTNo. (%) evaluable for most recent NFSTime to most recent NFS, y, median (range)Change in NFS, IQR, median (range)P
Overall 60     
Loes score at HCT     < .01 
    < 10 30 26 (87) 2.9 (0.2-8.3) 0 (−1 to 20), (0-1)  
    ≥ 10 30 18 (60) 2.1 (0.8-6.6) 7.5 (0-23), (4-19)  
NFS at HCT     < .01 
    0 23 20 (87) 2.2 (0.2-8.3) 0 (0-8), (0-0)  
    ≥ 1 37 24 (65) 2.3 (0.8-7.2) 7 (−1 to 23), (1-17.5)  
Performance IQ at HCT     < .01 
    ≥ 80 29 23 (79) 3.1 (0.5-8.5) 0 (−1 to 22), (0-1)  
    < 80 22 16 (73) 1 (0.2-5.2) 8 (0-23), (3-17.5)  
Full Scale IQ at HCT     < .01 
    ≥ 80 26 20 (77) 3.5 (0.5-8.5) 0 (−1 to 12), (0-1)  
    < 80 20 14 (70) 1 (0.2-5.2) 11 (0-23), (2-20)  
Donor chimerism at day 60     < .01 
    > 80% 30 29 (97) 3.1 (0.2-8.5) 0 (−1 to 20), (0-7)  
    ≤ 80% 19 16 (84) 0.5 (0.2-2) 8 (0-23), (6-20.5)  

IQR indicates interquartile range.

Close Modal

or Create an Account

Close Modal
Close Modal